Patents by Inventor Kevin J. Tracey

Kevin J. Tracey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8138141
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: March 20, 2012
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20110293640
    Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
    Type: Application
    Filed: May 27, 2011
    Publication date: December 1, 2011
    Inventors: Kevin J. Tracey, Valentin A. Pavlov
  • Patent number: 8053206
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: November 8, 2011
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Haichao Wang
  • Publication number: 20110268695
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: January 11, 2011
    Publication date: November 3, 2011
    Applicants: The Feinstein Institute for Medical Research, University of Pittsburgh of the Commonwealth System of Higher Education, The General Hospital Corporation
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, JR., Mitchell P. Fink
  • Publication number: 20110245286
    Abstract: Methods of inhibiting release of a proinflammatory cytokine from a macrophage are provided. The methods comprise treating the macrophage with a cholinergic agonist in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from the macrophage, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor. Methods for inhibiting an inflammatory cytokine cascade in a patient are also provided. The methods comprise treating the patient with a cholinergic agonist in an amount sufficient to inhibit the inflammatory cytokine cascade, wherein the cholinergic agonist is selective for an ?7 nicotinic receptor. Methods for determining whether a compound is a cholinergic agonist reactive with an ?7 nicotinic receptor are also provided. The methods comprise determining whether the compound inhibits release of a proinflammatory cytokine from a mammalian cell.
    Type: Application
    Filed: February 1, 2011
    Publication date: October 6, 2011
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: KEVIN J. TRACEY, HONG WANG
  • Patent number: 8003632
    Abstract: A method of treating a subject with a cytokine-mediated inflammatory disorder comprising administering to the subject an effective amount of a pharmaceutically acceptable cholinesterase inhibitor, provided that the inhibitor is not galantamine.
    Type: Grant
    Filed: August 14, 2007
    Date of Patent: August 23, 2011
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Valentin A. Pavlov
  • Publication number: 20110166148
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.
    Type: Application
    Filed: March 16, 2010
    Publication date: July 7, 2011
    Applicant: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Hong Wang
  • Publication number: 20110112128
    Abstract: A method of treating ileus in a subject by administering to the subject an effective amount of a pharmacological agent that increases the activity of cholinergic receptor in a subject. Examples of pharmacological agents are brain muscarinic agonist, cholinergic agonist or cholinesterase inhibitor. The methods of the present invention can be used to treat ileus caused by abdominal surgery, or administration of narcotics or chemotherapeutic agents such as during cancer chemotherapy.
    Type: Application
    Filed: July 20, 2010
    Publication date: May 12, 2011
    Inventors: Kevin J. Tracey, Mitchell P. Fink
  • Patent number: 7897569
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: March 1, 2011
    Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh of the Commonwealth System of Higher Education
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
  • Publication number: 20110020318
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Application
    Filed: January 19, 2010
    Publication date: January 27, 2011
    Inventors: Kevin J. Tracey, Huan Yang
  • Publication number: 20110015231
    Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VIIa). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.
    Type: Application
    Filed: September 27, 2010
    Publication date: January 20, 2011
    Inventors: Yousef Al-Abed, Kevin J. Tracey
  • Patent number: 7829097
    Abstract: Methods and compositions are disclosed for protecting an organ or tissue from inflammation and organ injury following ischemia, reperfusion, and trauma through the administration of an HMGB1 protein within a time period sufficient to protect the organ or tissue from injury.
    Type: Grant
    Filed: February 6, 2007
    Date of Patent: November 9, 2010
    Assignees: University of Pittsburgh - Of the Commonwealth System of Higher Education, The Feinstein Institute for Medical Research
    Inventors: Allan Tsung, Timothy R. Billiar, Mitchell P. Fink, Kevin J. Tracey
  • Publication number: 20100256341
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.
    Type: Application
    Filed: June 18, 2010
    Publication date: October 7, 2010
    Inventors: Kevin J. Tracey, Hong Wang
  • Patent number: 7807696
    Abstract: Compounds of Formula (I), pharmaceutical compositions comprising compounds of Formulae (I a) or (VII) and a method of treating a subject with an inflammatory cytokine-mediated disorder comprising administering to the subject a compound of Formulae (I a) or (VII a). The variables of Formulae (I), (I a), (VII) and (VII a) are described herein.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: October 5, 2010
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Yousef Al-Abed, Kevin J. Tracey
  • Patent number: 7785808
    Abstract: A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an ?7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory cytokine that is released from a macrophage wherein said condition is acute pancreatitis. The compounds of the present invention include a quaternary analog of cocaine; (1-aza-bicyclo[2.2.2]oct-3-yl)-carbamic acid 1-(2-fluorophenyl)-ethyl ester; a compound of formula (I), a compound of formula (II), a compound of formula (III), a compound of formula (IV), and an oligonucleotide or mimetic capable of attenuating the symptoms of acute pancreatitis wherein the oligonucleotide or mimetic consists essentially of a sequence greater than 5 nucleotides long that is complementary to an mRNA of an ?7 cholinergic receptor. The variables of formulae (I), (II), (III) and (IV) are described herein.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: August 31, 2010
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Hong Wang
  • Publication number: 20100172905
    Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
    Type: Application
    Filed: July 1, 2009
    Publication date: July 8, 2010
    Applicant: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
    Inventors: KEVIN J. TRACEY, HAICHAO WANG
  • Patent number: 7749959
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise a vertebrate HMGB A box, and an antibody preparation that specifically binds to a vertebrate HMGB B box. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of the proinflammatory cytokine, or to inhibit the inflammatory cytokine cascade.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: July 6, 2010
    Assignees: The Feinstein Institute for Medical Research, The General Hospital Corporation, University of Pittsburgh-of the Commonwealth System of Higher Education
    Inventors: Kevin J. Tracey, Huan Yang, Howland Shaw Warren, Jr., Mitchell P. Fink
  • Patent number: 7741372
    Abstract: There is disclosed a method for treating diseases and disorders involving T cell activation and HIV-infection using the p38 mitogen activated protein kinase (MAPK) signaling pathway as a target for intervention. There is further disclosed a use for guanylhydrazone-substituted compounds to treat diseases and disorders related to T cell activation and HIV-infection.
    Type: Grant
    Filed: July 16, 2003
    Date of Patent: June 22, 2010
    Assignee: Cytokine PharmaSciences, Inc.
    Inventors: Kevin J. Tracey, Pamela Cohen, Michael Bukrinsky, Helena Schmidtmayerova
  • Patent number: 7696169
    Abstract: The invention features a method of treating an inflammatory condition in an individual, comprising administering an agent inhibits the interaction between a Toll-like receptor 2 (TLR2) and a high mobility group B (HMGB) polypeptide to the individual. The invention also features methods for identifying agents that inhibit the interaction between TLR2 and HMGB.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 13, 2010
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Kevin J. Tracey, Huan Yang
  • Publication number: 20100040607
    Abstract: Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an agent that inhibits HMGB biological activity and a caspase inhibitor. The methods comprise treating a cell or a patient with sufficient amounts of the composition to inhibit the release of proinflammatory cytokine(s) and/or inhibit the inflammatory cytokine cascade.
    Type: Application
    Filed: May 11, 2006
    Publication date: February 18, 2010
    Inventors: Kevin J. Tracey, Huan Yang